Anti-SMYD3

Evaluated by Western Blotting in HEPG2 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected SMYD3 in 10 µg of HEPG2 cell lysate.

Anti-SMYD3, Cat. No. ABE2870, is a highly specific rabbit polyclonal antibody that targets Histone-lysine N-methyltransferase SMYD3 and has been tested in Chromatin Immunoprecipitation (ChIP) and Western Blotting.

Chromatin Immunoprecipitation Analysis: A representative lot detected SMYD3 in livers of 8.5 months old DEN-treated wild-type and Smyd3-KO mice (Sarris, M.E., et. al. (2016). Cancer Cell. 29(3):354-66).

Western Blotting Analysis: A representative lot detected SMYD3 in whole cell and nuclear extracts from the livers of 8.5 months-old untreated and DEN-treated (Sarris, M.E., et. al. (2016). Cancer Cell. 29(3):354-66).

Research Category
Epigenetics & Nuclear Function

This rabbit polyclonal antibody detects Histone-lysine N-methyltransferase SMYD3 in human and murine cells.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Histone-lysine N-methyltransferase SMYD3 (UniProt: Q9H7B4; also known as EC: 2.1.1.43, SET and MYND domain-containing protein 3, Zinc finger MYND domain-containing protein 1) is encoded by the SYMD3 (also known as ZMYND1, ZNFN3A1) gene (Gene ID: 64754) in human. SMYD3 is a member of the class V-like SAM-binding methyltransferase superfamily that specifically methylates ′Lys-4′ of histone H3, inducing di- and tri-methylation, but not monomethylation. The SET domain of SMYD3 shows histone H3-lysine 4 (H3-K4)-specific methyltransferase activity, which is enhanced in the presence of HSP90A. SMYD3 also contains a MYND-type zinc finger domain (aa 49-87). It plays an important role in transcriptional activation as a member of an RNA polymerase II complex. SMYD3 is mainly cytoplasmic when cells are arrested at G0/G1, but accumulates in the nucleus at S phase and G2/M phases. It is expressed in skeletal muscles and testis and its overexpression has been shown in a majority of colorectal and hepatocellular carcinomas. Introduction of SMYD3 into NIH3T3 cells is reported to enhance cell growth and the knockdown of this gene with SiRNA induces growth suppression in cancer cells. (Ref.: Hamamoto, R et al. (2004). Nat. Cell Biol. 6(8); 731-740; Sarris, ME et al. (2016). Cancer Cell 29(3); 354-366).

~49 kDa observed; 49.10 kDa calculated. Uncharacterized bands may be observed in some lysate(s).

Epitope: unknown

His-tagged full length recombinant human Histone-lysine N-methyltransferase SMYD3.

Concentration: Please refer to lot specific datasheet.

Format: Unpurified

Rabbit polyclonal antiserum with 0.05% sodium azide.

Unpurified

Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.